Federica Bertolini
YOU?
Author Swipe
View article: Other Than Complete Response in Oropharyngeal Carcinoma: Patient and Tumor‐Related Factors
Other Than Complete Response in Oropharyngeal Carcinoma: Patient and Tumor‐Related Factors Open
Objective Oropharyngeal carcinoma represents a tumor with an increased concern in human health and treatment strategy. This study aims to identify any tumor or patient‐related characteristics capable of predicting response to non‐surgical …
View article: CAR-T for Lung Cancers: Challenges and Innovations
CAR-T for Lung Cancers: Challenges and Innovations Open
Lung cancer (LC) is the leading cause of cancer mortality worldwide. Despite current therapies, including surgery, radiotherapy, targeted therapies, and immunotherapy, most patients experience relapse. Immune checkpoint inhibitors (ICIs) h…
View article: Supplementary Data 1 from INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Supplementary Data 1 from INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Open
Supplementary material
View article: Data from INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Data from INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Open
Purpose:Treatment options for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) after failure of immune checkpoint inhibitor treatment and platinum-based chemotherapy are limited. Preliminary data suggested that mona…
View article: Carboplatin, etoposide, atezolizumab, and bevacizumab in the first-line treatment of patients with extensive stage small-cell lung cancer: the GOIRC-01-2019 CeLEBrATE study
Carboplatin, etoposide, atezolizumab, and bevacizumab in the first-line treatment of patients with extensive stage small-cell lung cancer: the GOIRC-01-2019 CeLEBrATE study Open
Background The addition of a programmed death-ligand 1 (PD-L1) inhibitor, either atezolizumab or durvalumab, to platinum-etoposide prolonged survival in a limited subset of patients with extensive-stage small-cell lung cancer (ES-SCLC). Pr…
View article: INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Open
Purpose: Treatment options for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) after failure of immune checkpoint inhibitor treatment and platinum-based chemotherapy are limited. Preliminary data suggested that mon…
View article: Lenvatinib in Relapsed/Metastatic Adenoid Cystic Carcinoma: Real‐World Data From 17 Italian Centers
Lenvatinib in Relapsed/Metastatic Adenoid Cystic Carcinoma: Real‐World Data From 17 Italian Centers Open
Background Lenvatinib, a multi‐target tyrosine kinase inhibitor (MTKI), has demonstrated activity in recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC) in phase II studies. Methods This multicenter, retrospective study included p…
View article: Neratinib and the Role of Anti‐<scp>HER2</scp> Therapy in Salivary Duct Carcinoma
Neratinib and the Role of Anti‐<span>HER2</span> Therapy in Salivary Duct Carcinoma Open
Backgroud Salivary duct carcinoma (SDC) is a rare and aggressive malignancy with a generally dismal prognosis and no standard of care established, despite a known association with epidermal growth factor receptor 2 (HER2) and androgen rece…
View article: Current Radiotherapy Management of Extensive-Stage Small-Cell Lung Cancer in the Immunotherapy Era: An Italian National Survey on Behalf of the Italian Association of Radiotherapy and Clinical Oncology (AIRO)
Current Radiotherapy Management of Extensive-Stage Small-Cell Lung Cancer in the Immunotherapy Era: An Italian National Survey on Behalf of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) Open
Background: Extensive-stage small-cell lung cancer (ES-SCLC) treatment has recently been revolutionized by the advent of immune checkpoint inhibitors. This survey was conducted to evaluate the current pattern of care among Italian clinicia…
View article: Current Management of Extensive Stage Small Cell Lung Cancer in Italy: A National Survey on Behalf of Italian Association of Radiotherapy and Clinical Oncology (AIRO)
Current Management of Extensive Stage Small Cell Lung Cancer in Italy: A National Survey on Behalf of Italian Association of Radiotherapy and Clinical Oncology (AIRO) Open
Background: Extensive-stage SCLC (ES-SCLC) treatment has recently been revolutionized by the advent of immune checkpoint inhibitors. This survey was conducted to evaluate the current pattern of care among Italian clinicians, in particular …
View article: Complete and durable regression of leptomeningeal involvement during lorlatinib treatment in a patient with lung cancer
Complete and durable regression of leptomeningeal involvement during lorlatinib treatment in a patient with lung cancer Open
Metastatic spread to the central nervous system (CNS) is frequent in anaplastic lymphoma kinase ( ALK )-rearranged non-small cell lung cancer (NSCLC) and has an important impact on patient prognosis and quality of life. Leptomeningeal invo…
View article: High-dose statins are associated with increased aortic valve calcium load in patients with severe stenosis
High-dose statins are associated with increased aortic valve calcium load in patients with severe stenosis Open
Background AS represents the predominant valvular pathology, marked by the progressive fibro-calcific remodeling of aortic valve leaflets. This condition poses a significant clinical burden due to its association with increased morbidity a…
View article: Effect of statins on thoracic aortic disease: results from a meta-analysis and experimental data
Effect of statins on thoracic aortic disease: results from a meta-analysis and experimental data Open
Background Thoracic aortic aneurysms (TAAs) that progress to acute aortic dissections are often fatal. Numerous risk factors, such as smoking, uncontrolled hypertension, and dyslipidemia, lead to increased wall stress and adverse outcomes.…
View article: Rare Driver Mutations in Advanced, Oncogene-Addicted Non-Small Cell Lung Cancer: A North Italian, Real-World, Registry Experience
Rare Driver Mutations in Advanced, Oncogene-Addicted Non-Small Cell Lung Cancer: A North Italian, Real-World, Registry Experience Open
The real-world, retrospective, NEROnE registry investigated the impact of next-generation sequencing (NGS) in advanced non-small-cell lung cancer (NSCLC) patients (pts) at three oncology units in the north of Italy between January 2020 and…
View article: Sirt1 in focus: unveiling molecular insights and therapeutic prospects in calcific aortic stenosis with sglt2i inhibitors
Sirt1 in focus: unveiling molecular insights and therapeutic prospects in calcific aortic stenosis with sglt2i inhibitors Open
Funding Acknowledgements Type of funding sources: Foundation. Main funding source(s): Fondazione Gigi & Pupa Ferrari ONLUS Background Calcific aortic stenosis (AS) affects 3% of older adults and lacks medical treatment. The well-known deac…
View article: Essential data variables for a minimum dataset for head and neck cancer trials and clinical research: HNCIG consensus recommendations and database
Essential data variables for a minimum dataset for head and neck cancer trials and clinical research: HNCIG consensus recommendations and database Open
The Head and Neck Cancer International Group (HNCIG) has undertaken an international modified Delphi process to reach consensus on the essential data variables to be included in a minimum database for HNC research. Endorsed by 19 research …
View article: 91P Observational retro-prospective study on immune checkpoint inhibitors (ICIs) treatment duration in patients with advanced non-small cell lung cancer (aNSCLC) (I-STOP study)
91P Observational retro-prospective study on immune checkpoint inhibitors (ICIs) treatment duration in patients with advanced non-small cell lung cancer (aNSCLC) (I-STOP study) Open
Data on optimal ICI treatment duration in aNSCLC are scarce, especially in real-world (RW) settings. I-STOP is an ongoing observational, multicentre, retro-prospective study looking at aNSCLC patients (pts) treated with single-agent ICI fo…
View article: Metabolically activated and highly polyfunctional intratumoral VISTA+ regulatory B cells are associated with tumor recurrence in early stage NSCLC.
Metabolically activated and highly polyfunctional intratumoral VISTA+ regulatory B cells are associated with tumor recurrence in early stage NSCLC. Open
B cells have emerged as central players in the tumor microenvironment (TME) of non-small cell lung cancer (NSCLC). However, although there is clear evidence for their involvement in cancer immunity, scanty data exist on the characterizatio…
View article: Exploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study)
Exploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study) Open
We demonstrated the non-inferiority of a dexamethasone (DEX)-sparing (single-dose) regimen with NEPA, a netupitant/palonosetron fixed combination, for preventing chemotherapy-induced nausea and vomiting (CINV) caused by cisplatin. This pre…
View article: Oligorecurrent Non-Small-Cell Lung Cancer Treated by Chemo-Radiation Followed by Immunotherapy and Intracranial Radiosurgery: A Case Report and Mini Review of Literature
Oligorecurrent Non-Small-Cell Lung Cancer Treated by Chemo-Radiation Followed by Immunotherapy and Intracranial Radiosurgery: A Case Report and Mini Review of Literature Open
Locally advanced non-small-cell lung cancer still represents a “grey zone” in terms of the best treatment choice and optimal clinical outcomes. Indeed, most patients may be suitable to receive different treatments with similar outcomes suc…
View article: Dissecting Immunotherapy Strategies for Small Cell Lung Cancer: Antibodies, Ionizing Radiation and CAR-T
Dissecting Immunotherapy Strategies for Small Cell Lung Cancer: Antibodies, Ionizing Radiation and CAR-T Open
Small cell lung cancer (SCLC) is a highly aggressive malignancy that accounts for about 14% of all lung cancers. Platinum-based chemotherapy has been the only available treatment for a long time, until the introduction of immune checkpoint…